NCT07060989View on ClinicalTrials.gov

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions

Advanced Solid Tumors

Interventions

DRUG

NTS071

Oral administration

Trial Locations (2)

78201

Next Oncology, San Antonio

200032

Shanghai, Shanghai

All Listed Sponsors

lead

Nutshell Therapeutics (Shanghai) Co., LTD.

INDUSTRY